Patents by Inventor Sébastien Lalevée

Sébastien Lalevée has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • T CELL RECEPTORS THAT BIND TO NY-ESO-1 AND METHODS OF USE THEREOF
    Publication number: 20240102044
    Abstract: Provided are TCRs (e.g., TCRs that bind to NY-ESO-1), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.
    Type: Application
    Filed: March 27, 2023
    Publication date: March 28, 2024
    Applicant: MiNK Therapeutics, Inc.
    Inventors: Marc van Dijk, Volker Seibert, Cornelia Anne Mundt, Arthur Andrew Hurwitz, Mark Adrian Exley, Benjamin Jacob Wolf, Daniel Leventhal, Sébastien Lalevée, Reed Masakayan
  • T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof
    Patent number: 11718658
    Abstract: Provided are TCRs (e.g., TCRs that bind to MLL, e.g., TCRs that bind to an MLL phosphopeptide, e.g., TCRs that bind to an MLL phosphopeptide/MHC complex), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: August 8, 2023
    Assignee: MiNK Therapeutics, Inc.
    Inventors: Marc van Dijk, Ekaterina Vladimirovna Breous-Nystrom, Alessandra Franchino, Sébastien Lalevée, Arthur Andrew Hurwitz, Mark Adrian Exley, Benjamin Jacob Wolf
  • T cell receptors that bind to NY-ESO-1 and methods of use thereof
    Patent number: 11613764
    Abstract: Provided are TCRs (e.g., TCRs that bind to NY-ESO-1), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: March 28, 2023
    Assignee: MiNK Therapeutics, Inc.
    Inventors: Marc van Dijk, Volker Seibert, Cornelia Anne Mundt, Arthur Andrew Hurwitz, Mark Adrian Exley, Benjamin Jacob Wolf, Daniel Leventhal, Sébastien Lalevée, Reed Masakayan
  • T CELL RECEPTORS THAT BIND TO MIXED LINEAGE LEUKEMIA (MLL)-SPECIFIC PHOSPHOPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20200308246
    Abstract: Provided are TCRs (e.g., TCRs that bind to MLL, e.g., TCRs that bind to an MLL phosphopeptide, e.g., TCRs that bind to an MLL phosphopeptide/MHC complex), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.
    Type: Application
    Filed: March 3, 2020
    Publication date: October 1, 2020
    Inventors: Marc VAN DIJK, Ekaterina Vladimirovna BREOUS-NYSTROM, Alessandra FRANCHINO, Sébastien LALEVÉE, Andrew Arthur HURWITZ, Mark Adrian EXLEY, Benjamin Jacob WOLF
  • T CELL RECEPTORS THAT BIND TO NY-ESO-1 AND METHODS OF USE THEREOF
    Publication number: 20200040358
    Abstract: Provided are TCRs (e.g., TCRs that bind to NY-ESO-1), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.
    Type: Application
    Filed: July 15, 2019
    Publication date: February 6, 2020
    Inventors: Marc Van Dijk, Volker Seibert, Cornelia Anne Mundt, Arthur Andrew Hurwitz, Mark Adrian Exley, Benjamin Jacob Wolf, Daniel Leventhal, Sébastien Lalevée, Reed Masakayan
  • PREDICTION OF PREECLAMPSIA USING MICRORNA
    Publication number: 20160369343
    Abstract: The application relates to a method for predicting a risk for preeclampsia in a subject, said method comprising analysing a sample from the subject for the level of expression of miR455 and comparing the level of expression of miR455 in the sample from the subject to the levels of miR455 in a control sample, wherein a significantly lower expression of miR455 as compared to the expression of miR455 in the control is indicative of a risk for preeclampsia.
    Type: Application
    Filed: February 26, 2015
    Publication date: December 22, 2016
    Inventors: Marc BUEHLER, Sebastien LALEVEE, Olav LAPAIRE